Syntara Limited Shares Encouraging 52-Week Data for Amsulostat in Blood Cancer, Sets Stage for Phase 2b Trials in Late 2026

Amsulostat’s 52-Week Data Highlights Durability and Unique Safety Profile in Myelofibrosis

Syntara’s Phase 2a trial evaluated amsulostat, a pan-lysyl oxidase (LOX) inhibitor, combined with ruxolitinib in myelofibrosis patients, showing positive safety and tolerability over 52 weeks. Sixteen patients were enrolled, with 11 completing six months and 7 completing the full 12-month follow-up. The data indicate increasing and durable clinical benefits beyond 24 weeks, comparing favourably with other therapies in development for this indication.

Myelofibrosis, a rare bone marrow cancer affecting approximately 55,000 patients across major markets including the USA, Japan, and Europe, leads to scar tissue formation and abnormal blood cell proliferation, causing severe symptoms and a median survival of five years. Amsulostat’s mechanism—blocking lysyl oxidase to reduce tissue cross-linking and mechanical stress while suppressing growth factor signalling—targets the underlying bone marrow environment rather than just symptom management.

Orphan Drug Status and Market Potential in a US$2.8 Billion Annual Myelofibrosis Market

Amsulostat has FDA orphan drug designation for myelofibrosis and is developed as a first- and best-in-class pan-LOX inhibitor with extensive patent protection. Multiple peer-reviewed publications in Nature support its mechanism and clinical rationale. Final Phase 2a data presented at the American Society of Haematology (ASH) 2025 meeting confirmed its differentiated safety and efficacy profile. The myelofibrosis market is valued at approximately US$2.8 billion annually, with myelodysplastic syndrome adding an estimated US$3.2 billion, combining for over US$6 billion in potential commercial opportunity.

Current JAK inhibitors, the standard of care generating about US$1.9 billion annually, have significant limitations including limited survival benefits, dose-limiting toxicities, and high discontinuation rates. Amsulostat’s novel mode of action and improved tolerability, combined with compatibility with existing treatments, position it as a promising breakthrough for patients inadequately served by current therapies. Recent biotech acquisitions post-Phase 3 trials in myelofibrosis have surpassed US$1.7 billion, underscoring strong commercial interest.

Phase 2b Trial Set for Q4 2026 Following FDA Protocol Review

Syntara aims to start a Phase 2b trial of amsulostat in Q4 2026, with the protocol aligned to FDA guidance. The regulatory review of this protocol is a key near-term milestone that could catalyse partnerships or commercialisation discussions. This trial will build on the positive 52-week Phase 2a data to expand evidence of efficacy and safety across a broader patient population.

Alongside Phase 2b, two Phase 2 trials in myelodysplastic syndrome (AZALOX and MESSAGE) are progressing, with preliminary data expected in Q4 2026. MDS represents a distinct haematological malignancy market valued at about US$3.2 billion annually. These upcoming data releases are anticipated to enhance Syntara’s value proposition.

SNT-9465 Targets Fibrosis and Skin Scarring Market Worth US$50–55 Billion by 2030

Syntara’s secondary asset, SNT-9465, is in Phase 1b trials for hypertrophic scars, a condition with significant unmet medical needs. The global scar-treatment market is projected to reach between US$50 billion and US$55 billion by 2030. Topline safety and efficacy data from this trial are expected in H2 2026, representing a potential near-term catalyst.

The fibrosis and scar-treatment sector has attracted substantial investment due to the large affected population and limited therapies. SNT-9465 diversifies Syntara’s pipeline beyond blood cancers and could lead to partnership or accelerated development opportunities upon successful Phase 1b results.

SNT-4728 Parkinson’s Disease Programme Advances with Final Data Due Q3 2026

SNT-4728, Syntara’s third clinical asset, is being evaluated in a Phase 2 programme targeting Parkinson’s disease and isolated rapid eye movement sleep behaviour disorder (iRBD). Preliminary data have been reported, with final results anticipated in Q3 2026. The global Parkinson’s disease market is forecast to reach US$7.6 billion by 2030, highlighting significant commercial potential.

Including iRBD, a potential early biomarker for Parkinson’s, expands the programme’s clinical scope and commercial appeal. The Q3 2026 data release will be critical for assessing the asset’s viability and potential for partnerships or advancement.

Strong Financial Position and Institutional Support Back Pipeline Through FY28

As of 30 June 2026, Syntara held A$13.5 million in cash, sufficient to fund operations into FY28. The company’s market capitalisation was A$47 million on 23 July 2026, with an enterprise value of A$33.5 million and a share price of A$0.024. Over the past three years, Syntara secured A$11.5 million in non-dilutive grants, reducing equity dilution.

Institutional investors own over 44% of the company, including D&A Income Limited (18%) and Platinum Investment Management Limited (12%). Broker coverage from Canaccord Genuity, Euroz Hartleys, Bell Potter, and Evolution Capital reflects strong analyst interest. The management team has a proven track record, having raised over A$100 million and executed licensing deals, supporting confidence in advancing programmes and securing partnerships.

Diversified Pipeline Strategy Mitigates Risk Across Multiple Therapeutic Areas

Syntara’s pipeline advances three key assets targeting haematological malignancies, fibrosis, and neurodegenerative diseases, each addressing large markets. This multiple shots on goal approach reduces reliance on any single programme and increases the likelihood of commercial success. The combined addressable market for the three Phase 2 blood cancer indications exceeds US$4.5 billion annually, with additional significant markets in fibrosis and Parkinson’s disease.

Additional Phase 1 and preclinical assets provide longer-term growth potential. The company’s extensive patent portfolio supports extended exclusivity and multiple revenue streams across indications. This strategy aligns with investor expectations for clinical-stage biotech firms focused on high unmet medical needs.

Upcoming Catalysts and Value Drivers Through 2026 and 2027

Key upcoming milestones include the FDA’s review of the amsulostat Phase 2b protocol ahead of Q4 2026 trial initiation, which could validate development plans and spark partnership interest. Preliminary data from AZALOX and MESSAGE myelodysplastic syndrome studies in Q4 2026 will further demonstrate amsulostat’s potential across blood cancers.

Additional catalysts include H2 2026 Phase 1b data for SNT-9465 in hypertrophic scarring and Q3 2026 final results from the SNT-4728 Parkinson’s disease and iRBD trial. These sequential data releases are expected to sustain investor attention and provide opportunities for valuation reassessment.

Regulatory and Commercial Risks Remain Integral to Development Outlook

Syntara’s progress depends on successful clinical trial completion, regulatory approvals, and commercialisation of its drug candidates. The company acknowledges risks including potential safety or efficacy setbacks, patient recruitment challenges, and adverse events that could delay or halt programmes. Outcomes of ongoing Phase 2 trials in myelofibrosis, myelodysplastic syndrome, fibrosis, and neurodegenerative diseases remain uncertain and may differ materially from expectations.

Partnership and commercial risks are also significant. Securing development and licensing agreements with larger pharmaceutical companies on favourable terms is not guaranteed. Market adoption depends on physician and patient acceptance, reimbursement, competition, and supply chain factors. Limited financial resources heighten the importance of strategic partnerships. Maintaining robust patent protection is critical for long-term commercial success and defending against competition.